About Adagrasib Adagrasib is a prescription medicine used in adults: alone to treat non-small cell lung…
About Cejemly® (Sugemalimab) The anti-PD-L1 monoclonal antibody sugemalimab was discovered by CStone using the OmniRat® transgenic animal…
About Pralsetinib Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth. Pralsetinib is a medication approved for RET mutation-positive medullary…
ABout Crizotinib Crizotinib is a prescription medicine used to treat people with non-small cell lung cancer…
About Repotrectinib Repotrectinib is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth. Repotrectinib is…
About Encorafenib Encorafenib is a medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets…
Melanoma Indicated in combination with encorafenib for patients with unresectable or metastatic melanoma with a BRAF…
Larotrectinib Larotrectinib is a medication for the treatment of cancer.It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. …
Larotrectinib Larotrectinib is a medication for the treatment of cancer.It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. …
Tevimbra (Tislelizumab-jsgr) sold under the brand name 百泽安 in china, is a humanized IgG4 anti–PD-1 monoclonal…
Zerpidio (Serplulimab) sold under the brand name 汉斯状 in china. Serplulimab, a recombinant humanised anti-PD-1 monoclonal…
Avzivi® (Bevacizumab-tnjn) sold under the brand name POBEVCY (普贝希) in China, is a humanized monoclonal antibody…
Larotrectinib is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change.…
The targeted drug selpercatinib has been a treatment option for some people with lung cancer or…
Non-small Cell Lung Cancer Indicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors…
Trametinib is a kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers…
Copyright © 2021-2022 LienTeh.net All rights reserved.
